rti-336
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2008 (NCT00808119)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Dopamine transporterINHIBITOR
SLC6A3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(-c2cc([C@@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)on2)cc1- Mol. weight
- 392.93 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1186581 ↗
Also known as
- 3beta-(4-chlorophenyl) tropane-2beta-(3-(4'-methylphenyl) isoxazol-5-yl) hydrochloride
- 8-azabicyclo(3.2.1)octane, 3-(4-chlorophenyl)-8-methyl-2-(3-(4-methylphenyl)-5-isoxazolyl)-, hydrochloride (1:1), (1r,2s,3s,5s)-
- rti 336
- rti-336
- rti-336
- rti-336
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01601717 | Phase 1 | Jan 1, 2010 | Baylor University, National Institute on Drug Abuse (NIDA) |
| NCT00808119 | Phase 1 | Oct 1, 2008 | Comprehensive Clinical Development, Inc., National Institute on Drug Abuse (NIDA), RTI International |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute on Drug Abuse (NIDA) | Government | 2 | 0 | 1 | 2008 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Comprehensive Clinical Development, Inc. | For profit | 1 | 0 | 1 | 2008 |
| RTI International | Academic/Hospital | 1 | 1 | 1 | 2008 |
4 organizations
Page 1 / 1